Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (211-220 of 512) with videos related to

Pageof 52
Sort By:
Bulletin Du Cancer|December 10, 2013
Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patientsSylvestre Le Moulec, Julien Hadoux, Eric Gontier, et al.
Expert Review of Molecular Diagnostics|November 14, 2015
The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancerKirsty Ross, Emma Pailler, Vincent Faugeroux, et al.
JTO Clinical and Research Reports|February 24, 2025
Personalized Therapy in a Patient With <i>EGFR</i>-Mutated NSCLC Developing Sequential <i>CCDC6-RET</i> Fusion and <i>BRAF</i> V600E Mutation as Bypass Resistance MechanismsArianna Marinello, Claudia Parisi, Damien Vasseur, et al.
Clinical Lung Cancer|August 16, 2021
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma PatientsJordi Remon, Nicolas Girard, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2023
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural MesotheliomaMarco Tagliamento, Massimo Di Maio, Jordi Remon, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2024
Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trialsEdouard Auclin, Matthieu Roulleaux Dugage, Teresa Gorria, et al.
Critical Reviews in Oncology/Hematology|February 19, 2011
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologistsStephane Ederhy, Hassan Izzedine, Christophe Massard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2013
Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncologyCharles Ferté, Andrew D Trister, Erich Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2022
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive DiseaseSai-Hong I Ou, Benjamin J Solomon, Alice T Shaw, et al.
Annals of Diagnostic Pathology|May 23, 2020
Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 casesVincent Thomas de Montpréville, Ludovic Lacroix, Etienne Rouleau, et al.
Pageof 52

Showing results (211-220 of 512) with videos related to

Sort By:
Pageof 52
Bulletin Du Cancer|December 10, 2013
Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patientsSylvestre Le Moulec, Julien Hadoux, Eric Gontier, et al.
Expert Review of Molecular Diagnostics|November 14, 2015
The potential diagnostic power of circulating tumor cell analysis for non-small-cell lung cancerKirsty Ross, Emma Pailler, Vincent Faugeroux, et al.
JTO Clinical and Research Reports|February 24, 2025
Personalized Therapy in a Patient With <i>EGFR</i>-Mutated NSCLC Developing Sequential <i>CCDC6-RET</i> Fusion and <i>BRAF</i> V600E Mutation as Bypass Resistance MechanismsArianna Marinello, Claudia Parisi, Damien Vasseur, et al.
Clinical Lung Cancer|August 16, 2021
PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma PatientsJordi Remon, Nicolas Girard, Silvia Novello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 11, 2023
Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural MesotheliomaMarco Tagliamento, Massimo Di Maio, Jordi Remon, et al.
Lung Cancer (Amsterdam, Netherlands)|November 29, 2024
Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trialsEdouard Auclin, Matthieu Roulleaux Dugage, Teresa Gorria, et al.
Critical Reviews in Oncology/Hematology|February 19, 2011
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologistsStephane Ederhy, Hassan Izzedine, Christophe Massard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2013
Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncologyCharles Ferté, Andrew D Trister, Erich Huang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 13, 2022
Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive DiseaseSai-Hong I Ou, Benjamin J Solomon, Alice T Shaw, et al.
Annals of Diagnostic Pathology|May 23, 2020
Non-small cell lung carcinomas with CTNNB1 (beta-catenin) mutations: A clinicopathological study of 26 casesVincent Thomas de Montpréville, Ludovic Lacroix, Etienne Rouleau, et al.
Pageof 52